Neurocrine Biosciences
NBIX
456 hedge funds and large institutions have $8.68B invested in Neurocrine Biosciences in 2023 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 165 increasing their positions, 186 reducing their positions, and 70 closing their positions.
57% more funds holding in top 10
Funds holding in top 10: 7 → 11 (+4)
37% more call options, than puts
Call options by funds: $51.6M | Put options by funds: $37.7M
0.03% less ownership
Funds ownership: 94% → 93.97% (-0.03%)
6% less capital invested
Capital invested by funds: $9.22B → $8.68B (-$543M)
6% less funds holding
Funds holding: 486 → 456 (-30)
11% less repeat investments, than reductions
Existing positions increased: 165 | Existing positions reduced: 186
41% less first-time investments, than exits
New positions opened: 41 | Existing positions closed: 70
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$81.3M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$75.7M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$73.6M |
| 4 |
Man Group
London,
United Kingdom
|
+$61.6M |
| 5 |
IC
IEQ Capital
Foster City,
California
|
+$47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Congress Asset Management
Boston,
Massachusetts
|
-$89.3M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$72.4M |
| 3 |
DM
Deerfield Management
New York
|
-$52.3M |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
-$31.7M |
| 5 |
Renaissance Technologies
New York
|
-$29.7M |
NBIX Hedge Fund Activity: Q2 2023 in Review
456 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q2 2023, worth a combined $8.68B — down 5.9% from $9.22B a quarter earlier.
Sellers outnumbered buyers: 70 funds closed out of NBIX and 41 opened new positions — a net loss of 29 holders — while 186 trimmed existing stakes and 165 added.
The largest buyer was Citadel Advisors, adding an estimated $81.3M. The largest seller was Congress Asset Management, cutting an estimated $89.3M.
- 456 institutional investors held Neurocrine Biosciences (NBIX) as of Q2 2023, down from 486 in Q1 2023.
- Funds reported $8.68B of Neurocrine Biosciences stock for Q2 2023, down 5.9% quarter-over-quarter.
- 41 funds opened new Neurocrine Biosciences positions in Q2 2023 and 70 closed out, a net change of -29 holders.
- The largest Neurocrine Biosciences buyer in Q2 2023 was Citadel Advisors, an estimated $81.3M added.
- The largest Neurocrine Biosciences seller in Q2 2023 was Congress Asset Management, an estimated $89.3M sold.
Based on aggregated 13F filings for Q2 2023.